# OnCo record ramp-201 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/ramp-201/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "ramp-201", "NCT04625270" ;
  schema:name "RAMP 201"@en ;
  schema:description "RAMP 201 produced the first approved treatment designed for low-grade serous ovarian cancer, a slow-growing type driven by the RAS pathway that shrugs off chemotherapy."@en ;
  schema:url <https://onco.cc/trials/ramp-201/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04625270>, <https://www.mskcc.org/news/fda-approves-avutometinib-defactinib-combination-for-treating-recurrent-low-grade-serous-ovarian-cancer-with-kras-mutation> ;
  onco:status "positive" ;
  onco:phase "2" ;
  schema:startDate "2020-12-21" ;
  onco:cancers <https://onco.cc/cancers/ovarian/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/kras/> ;
  onco:drugs <https://onco.cc/drugs/avutometinib-defactinib/> ;
  onco:companies <https://onco.cc/companies/verastem/> ;
  onco:pathways <https://onco.cc/pathways/ras-mapk/> ;
  onco:terms <https://onco.cc/terms/lgsoc/> .